AMLXHealthcare · Drug Manufacturers - Specialty & GenericThe 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. hold a median 12-month price target of $42 — +10.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Amylyx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Revisions (34): Analysts have, on balance, been cutting their forecasts.
Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AMLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.1% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | Baird | Maintains | Outperform | $28 → $52 |
| 19 Aug 2026 | Guggenheim | Maintains | Buy | $40 → $55 |
| 19 Aug 2026 | Mizuho | Maintains | Outperform | $30 → $42 |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $34 → $55 |
| 17 Aug 2026 | Mizuho | Maintains | Outperform | $24 → $30 |
| 3 Aug 2026 | Citigroup | Maintains | Buy | — |
| 3 Aug 2026 | Citigroup | Maintains | Buy | $20 → $26 |
| 20 July 2026 | Mizuho | Maintains | Outperform | — |
| 20 July 2026 | Mizuho | Maintains | Outperform | $21 → $24 |
| 25 June 2026 | Guggenheim | Maintains | Buy | — |
| 25 June 2026 | Guggenheim | Maintains | Buy | $30 → $40 |
| 28 Apr 2026 | Mizuho | Maintains | Outperform | — |
| 25 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Mar 2026 | Stifel | Initiates | Buy | — |
| 20 Feb 2026 | B of A Securities | Maintains | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Oct 2025 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMLX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Amylyx Pharmaceuticals, Inc. returned +310.2% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 6% of US stocks
Cheaper than 90% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Amylyx Pharmaceuticals, Inc. has a market value of $4.3B and an enterprise value of $4.1B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$152.1M.
Diluted earnings per share, trailing twelve months: $−1.43.
Free cash flow in the twelve months to 30 June 2026: −$126.7M.
Trailing P/E: 2.5×; forward P/E: −33.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Amylyx Pharmaceuticals, Inc. employs 136 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Amylyx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Amylyx Pharmaceuticals' stock rose nearly 79% this week after analysts raised their price targets on the company and it launched a new round of capital raising.
Why it matters — For an Amylyx watcher, the sharp stock surge and analyst price-target hikes signal renewed investor confidence, while the capital raise could fund future operations or pipeline development.
Amylyx Pharmaceuticals announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at $35.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same price, less underwriting discounts and commissions.
Why it matters — AMLX watchers would care because this capital raise increases the company's cash position through the sale of new shares, which dilutes existing shareholders.
Amylyx's stock rose after its drug avexitide reduced hypoglycemic events by 55% in the Phase III LUCIDITY study, positioning the company for an FDA filing in post-bariatric hypoglycemia by the end of 2026.
Why it matters — The Phase III win and planned FDA filing signal progress for avexitide, a key pipeline candidate for Amylyx shareholders.
Amylyx Pharmaceuticals' stock rose sharply after the company reported that its experimental GLP-1 treatment for chronic low blood sugar showed a favorable safety profile in a clinical study.
Why it matters — The positive safety data from the clinical study represents a notable development for Amylyx's GLP-1 pipeline candidate.
Amylyx Pharmaceuticals announced it has commenced an underwritten public offering of $350.0 million of shares of its common stock. The company also intends to grant underwriters a 30-day option to purchase up to an additional $52.5 million of shares at the public offering price, less underwriting discounts and commissions.
Why it matters — The proposed offering reflects a significant capital raise that will affect Amylyx's share count, existing shareholders' ownership, and the company's cash position.
The 12 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. have a median 12-month price target of $42, with estimates ranging from $20 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Amylyx Pharmaceuticals, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amylyx Pharmaceuticals, Inc. 56 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Amylyx Pharmaceuticals, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +10.1% from the last close, and Ticker Nerd's factor model ranks Amylyx Pharmaceuticals, Inc. 56 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amylyx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $55 over the next 12 months.
Amylyx Pharmaceuticals, Inc. returned +310.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases and endocrine conditions.
The most recent item we track (The Motley Fool, 21 Aug 2026): "Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week". Amylyx Pharmaceuticals' stock rose nearly 79% this week after analysts raised their price targets on the company and it launched a new round of capital raising.
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases and endocrine conditions. The company’s current pipeline includes investigational programs such as avexitide, a GLP-1 receptor antagonist studied for post-bariatric hypoglycemia and congenital hyperinsulinism, as well as candidates being evaluated for rare neurological and metabolic disorders. Amylyx Pharmaceuticals, Inc. concentrates on diseases with high unmet medical need and applies biomarker-driven and mechanistic research to guide its drug development efforts. Based in Cambridge, Massachusetts, the company operates as a single business segment centered on research and development of novel therapeutics for serious conditions.
CEO Mr. Joshua B. Cohen · 136 employees · United States · https://amylyx.com
